MESO - Mesoblast - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

997.2M

Cash

71.32M

Avg Qtr Burn

-15.82M

Short % of Float

0.13%

Insider Ownership

0.00%

Institutional Own.

1.70%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RYONCIL™ (Remestemcel-L) Details Acute graft-versus host disease	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REVASCOR® (Rexlemestrocel) Details Heart disease, Heart failure	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rexlemestrocel Details Chronic lower back pain	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Remestemcel-L Details Inflammatory bowel disease, Bowel disorder, Crohns disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Remestemcel-L (mesenchymal stem cells) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.